| Basics |
ABBVIE INC.
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
|
| IPO Date: |
December 14, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$399.57B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.02 | 1.02%
|
| Avg Daily Range (30 D): |
$2.53 | 1.12%
|
| Avg Daily Range (90 D): |
$2.00 | 0.91%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
6.23M |
| Avg Daily Volume (30 D): |
4.19M |
| Avg Daily Volume (90 D): |
3.98M |
| Trade Size |
| Avg Trade Size (Sh.): |
105 |
| Avg Trade Size (Sh.) (30 D): |
47 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Inst.Trades: |
62,639 |
| Avg Inst. Trade: |
$10.14M |
| Avg Inst. Trade (30 D): |
$26.86M |
| Avg Inst. Trade (90 D): |
$28.66M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
19 |
| Market Closing Trades |
| Avg Closing Trade: |
$86.86M |
| Avg Closing Trade (30 D): |
$242.57M |
| Avg Closing Trade (90 D): |
$224.78M |
| Avg Closing Volume: |
771.42K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.1
|
$.52
|
|
Diluted EPS
|
|
$.1
|
$.52
|
|
Revenue
|
$
|
$ 15.78B
|
$ 15.42B
|
|
Gross Profit
|
$
|
$ 10.47B
|
$ 11.08B
|
|
Net Income / Loss
|
$
|
$ 188M
|
$ 941M
|
|
Operating Income / Loss
|
$
|
$ 1.9B
|
$ 4.89B
|
|
Cost of Revenue
|
$
|
$ 5.3B
|
$ 4.35B
|
|
Net Cash Flow
|
$
|
$ -838M
|
$ 1.29B
|
|
PE Ratio
|
|
|
|
|
|
|
